Hua Long

US Patent:

20120148586, Jun 14, 2012

Filed:

Aug 19, 2009

Appl. No.:

13/392244

Inventors:

Joyce Ching Tsu Chou - San Jose CA, US
Chia-Yang Lin - Palo Alto CA, US
Hua Long - San Carlos CA, US

International Classification:

A61K 39/395
A61P 25/00
A61K 38/00

US Classification:

4241341, 4241301, 514 177

Abstract:

Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies.

US Patent:

20100086997, Apr 8, 2010

Filed:

Dec 5, 2007

Appl. No.:

12/519743

Inventors:

Chia-Yang Lin - Palo Alto CA, US
Hua Long - Stanford CA, US
David Liang Tsao - Cupertino CA, US

International Classification:

C12N 5/12
C07K 14/475
C07K 16/00

US Classification:

435346, 530350, 5303871, 5303881

Abstract:

Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies.

US Patent:

20230035072, Feb 2, 2023

Filed:

Dec 11, 2020

Appl. No.:

17/784579

Inventors:

- South San Francisco CA, US
Michael F. WARD - San Francisco CA, US
Hua LONG - San Carlos CA, US
Shiao-Ping LU - Los Altos CA, US
Omer Rizwan SIDDIQUI - Redwood City CA, US
Arnon ROSENTHAL - Woodside CA, US

Assignee:

Alector LLC - South San Francisco CA

International Classification:

C07K 16/28
A61P 25/28

Abstract:

The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.

US Patent:

20230024528, Jan 26, 2023

Filed:

Dec 4, 2020

Appl. No.:

17/782127

Inventors:

- South San Francisco CA, US
Ilaria TASSI - South San Francisco CA, US
Arnon ROSENTHAL - Woodside CA, US
Hua LONG - San Carlos CA, US
Santiago Viveros SALAZAR - South San Francisco CA, US

Assignee:

Alector LLC - South San Francisco CA

International Classification:

C07K 16/28
A61P 25/28

Abstract:

The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.

US Patent:

20210284710, Sep 16, 2021

Filed:

Nov 3, 2020

Appl. No.:

17/088149

Inventors:

- South San Francisco CA, US
Samuel Nalle - Pacifica CA, US
Jeonghoon Sun - San Francisco CA, US
Hua Long - San Carlos CA, US
Rashmi Bankoti - San Carlos CA, US

Assignee:

Alector LLC - South San Francisco CA

International Classification:

C07K 14/705
A61P 35/00
A61P 35/04
C07K 16/28
A61K 45/06
A61K 38/17

Abstract:

The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

US Patent:

20210079074, Mar 18, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943123

Inventors:

- South San Francisco CA, US
Muhammad A. ALHAWAGRI - San Francisco CA, US
Philip Ling KONG - San Francisco CA, US
Herve RHINN - San Francisco CA, US
Hua LONG - San Carlos CA, US
Karpagam SRINIVASAN - San Jose CA, US
Ananya MITRA - Menlo Park CA, US
Daniel P. BERMINGHAM - San Francisco CA, US
Klaus-Dieter HEGER - San Mateo CA, US
Santiago Viveros SALAZAR - San Carlos CA, US
Francesca CIGNARELLA - South San Francisco CA, US
Ilaria TASSI - San Francisco CA, US
Tina SCHWABE - San Francisco CA, US
Angie Grace YEE - San Francisco CA, US
Arnon ROSENTHAL - Woodside CA, US

International Classification:

C07K 16/18

Abstract:

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

US Patent:

20210069326, Mar 11, 2021

Filed:

Nov 19, 2020

Appl. No.:

16/952620

Inventors:

- DARMSTADT, DE
- NEW YORK NY, US
Alessandra DI PIETRO - Opera, IT
David FONTANA - Clyde Hill WA, US
Zelanna GOLDBERG - San Diego CA, US
Chia-Yang LIN - Palo Alto CA, US
Hua LONG - San Carlos CA, US
Marcella MARTIGNONI - Milan, IT
Dimitry Serge Antoine NUYTEN - San Francisco CA, US
Aron David THALL - San Diego CA, US
Adrian WOOLFSON - New York NY, US

International Classification:

A61K 39/395
A61K 31/4439
C07K 16/24
C07K 16/28
A61K 45/06
A61P 35/00
A61K 31/4184
A61K 31/706
A61K 33/24

Abstract:

The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

US Patent:

20200392229, Dec 17, 2020

Filed:

Jun 10, 2020

Appl. No.:

16/898307

Inventors:

- South San Francisco CA, US
Michael F. WARD - San Francisco CA, US
Hua LONG - San Carlos CA, US
Shiao-Ping LU - Los Altos CA, US
Omer Rizwan SIDDIQUI - Redwood City CA, US
Arnon ROSENTHAL - WOODSIDE CA, US
Herve RHINN - Paris, FR

Assignee:

Alector LLC - South San Francisco CA

International Classification:

C07K 16/28
G01N 33/68

Abstract:

The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.